Floatz logo

Ritlecitinib

Sezary Syndrome

Icahn School of Medicine at Mount SinaiSmall moleculePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Sezary Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BB
PREDNISONE TABLETS
Shanghai Jiao Tong University School of Medicine
Phase 4BB
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BB
CYCLOSPORIN A
Ohio State University Comprehensive Cancer Center
Phase 2BB
MOGAMULIZUMAB
Kyowa Kirin Co., Ltd.
Phase 2B

View all 40 →

Same molecule, other indications

Ritlecitinib is also rated in:

Alopecia AreataDormant
CCC
Indicative ·
52 / 100
View asset →
celiac diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →